Onyx Pharma Upgraded to Neutral
March 18, 2011 at 10:31 AM EDT
We have upgraded our rating on Onyx Pharmaceuticals, Inc. (ONXX) to Neutral from Underperform following the release of fourth quarter and fiscal year 2010 financial results. We were pleased to see an improvement in Nexavar sales. Global Nexavar sales, recorded by Bayer Healthcare (BAYRY), amounted to $934.0 million and $257.4 million for the full year [...]
